Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
Azenta has published its 2025 Environmental, Social, and Governance (ESG) Report. This report highlights the company's commitment and progress across various ESG initiatives.
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Azenta, Inc. - AZTA
Pomerantz LLP is investigating potential securities fraud claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of its investors. This investigation follows Azenta's announcement of disappointing Q2 fiscal 2026 financial results, including execution gaps, a cautious demand environment, and a $149 million goodwill impairment charge. The company also reduced its full-year fiscal 2026 outlook, leading to a significant 25.31% drop in its stock price on May 6, 2026.
Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
Azenta (NASDAQ: AZTA) has published its 2025 ESG report, detailing significant progress in environmental protection, social impact, and responsible operations. Key highlights include the first-time disclosure of Scope 3 GHG emissions, a target for 45% absolute reduction in Scope 1 and 2 emissions by FY2033, and sourcing 72% of its electricity from renewable sources. The report also notes a 40% reduction in Scope 1 and 2 carbon footprint compared to FY2022, expanded sustainable products, and enhanced employee well-being programs.
Why is Azenta (AZTA) Trading So Low Despite Strong Balance Sheet
Azenta (AZTA) is trading near its 52-week low despite a strong balance sheet, including a low Price-to-Book ratio and a significant net cash position. The company is undergoing a strategic transformation to a pure-play life sciences entity, which has led to mixed financial performance and investor uncertainty. While analysts have a "Strong Buy" consensus with a high price target, execution risks, macroeconomic headwinds, and integration challenges are contributing to the current skeptical valuation.
Levi & Korsinsky Announces Investigation of Securities Claims Against Azenta, Inc. (AZTA)
Levi & Korsinsky, LLP has announced an investigation into securities claims against Azenta, Inc. (AZTA) following significant losses incurred by investors. This investigation comes after Azenta disclosed a $149 million goodwill impairment and slashed its full-year guidance in May 2026, just three months after reaffirming strong organic revenue growth and margin expansion targets to investors. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to discuss potential legal rights.
AZTA Investor Alert: Levi & Korsinsky Investigates Azenta, Inc. (AZTA) for Potential Securities Fraud
Levi & Korsinsky, LLP is investigating Azenta, Inc. (AZTA) for potential securities fraud following the company's Q2 FY 2026 results. Azenta reported a $160.8 million net loss and a $149 million goodwill impairment charge, significantly contradicting earlier guidance that had been reaffirmed just three months prior. Investors who suffered losses after purchasing AZTA shares are encouraged to contact Levi & Korsinsky to discuss their legal rights.
Bronstein, Gewirtz & Grossman, LLC Encourages Azenta, Inc. (AZTA) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors of Azenta, Inc. (NASDAQ:AZTA) following a significant drop in its stock price. The investigation stems from Azenta's Q2 2026 financial results, which missed consensus estimates and included a $149 million goodwill impairment, leading to a downward revision of its 2026 outlook. Investors are encouraged to contact the firm to assist with the securities investigation.
Azenta (AZTA) director adds 10,000 shares through family trusts
Azenta, Inc. director William L. Cornog indirectly purchased 10,000 shares of common stock on May 18, 2026, at a weighted average price of $16.38 per share through family trusts. This transaction increased his indirect holdings to 19,703 shares, signaling positive sentiment. The purchase was an open-market transaction, with prices ranging from $16.19 to $16.52 per share and gives Cornog investment and voting power over these shares.
Bragar Eagel & Squire, P.C. is Investigating Azenta, Inc.
Bragar Eagel & Squire, P.C. has launched an investigation into Azenta, Inc. (NASDAQ: AZTA) on behalf of its stockholders. This follows Azenta's announcement of disappointing Q2 fiscal 2026 results, revised full-year guidance, and a significant drop in share price. The law firm is investigating potential violations of federal securities laws and other unlawful business practices by Azenta.
Azenta (AZTA) SVP uses 3,621 shares to cover RSU tax withholding
Azenta, Inc. SVP, General Counsel & Secretary Starr Ephraim disposed of 3,621 shares of common stock at $16.02 per share to cover tax withholdings related to the vesting of 12,593 restricted stock units on May 15, 2026. After this transaction, Ephraim directly holds 68,393 shares of Azenta common stock. This tax-related disposition is a standard procedure and not an open-market sale.
AZTA Investors Have Opportunity to Join Azenta, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Azenta, Inc. (AZTA) on behalf of investors for potential securities law violations. This follows Azenta's Q2 2026 financial results, which missed analyst estimates for revenue and earnings per share, leading to a 25.3% drop in share price. The firm is examining whether the company made false or misleading statements to investors.
AZTA Investors Have Opportunity to Join Azenta, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Azenta, Inc. (NASDAQ: AZTA) for potential securities law violations after the company missed Q2 2026 revenue and earnings estimates, attributing it to "execution-related shortfalls" and a "cautious prolonged demand environment." Following this news and a reduced full-year outlook, Azenta's shares fell by 25.3%. Shareholders who suffered losses are encouraged to contact the firm to discuss their rights.
INVESTOR ALERT: Investigation of Azenta, Inc. (AZTA) announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has initiated an investigation into Azenta, Inc. (NASDAQ: AZTA) to determine if the company violated federal securities laws. This follows Azenta's announcement on May 5, 2026, of disappointing Q2 fiscal 2026 results and a revised outlook, missing revenue consensus estimates. The company attributed this to a "more cautious prolonged demand environment" in North America, leading to a drop in its stock price.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Azenta, Inc. (AZTA) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Azenta, Inc. (AZTA) following the company's Q2 2026 financial results which missed estimates, included a $149 million goodwill impairment, and led to a reduced 2026 outlook. The firm is encouraging investors who purchased Azenta securities to reach out for additional information and to assist with the investigation. Azenta's stock price fell significantly after the announcement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Pomerantz LLP is investigating potential securities fraud claims against Azenta, Inc. (AZTA) on behalf of investors. This comes after Azenta reported lower-than-expected Q2 2026 financial results, including a $149 million goodwill impairment charge and reduced its full-year fiscal 2026 outlook. Following this news, Azenta's stock price dropped by over 25%.
Azenta (AZTA) price target decreased by 19.88% to 29.07
This article reports a significant 19.88% decrease in the price target for Azenta (AZTA), bringing it down to $29.07. The information is sourced from MSN.
AZTA SHAREHOLDER INVESTIGATION: Levi & Korsinsky
Levi & Korsinsky, LLP is investigating Azenta, Inc. (NASDAQ: AZTA) for potential securities law violations after the company disclosed a $149 million goodwill impairment and cut its FY 2026 guidance. This announcement came weeks after Azenta had reaffirmed confidence in its growth trajectory. The investigation focuses on whether Azenta made misleading statements regarding its Multiomics segment and the underlying factors of the impairment.
Azenta, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Azenta, Inc. (AZTA)
Levi & Korsinsky has initiated an investigation into Azenta, Inc. (NASDAQ: AZTA) following a significant drop in its stock price. The investigation stems from the company's Q2 FY 2026 earnings report, which revealed a $160.8 million GAAP net loss, primarily due to a $149 million goodwill impairment, contradicting previous positive guidance. Shareholders who incurred losses are encouraged to contact Levi & Korsinsky to discuss their legal rights regarding potentially misleading statements made by Azenta regarding its financial performance.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Announced
Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Azenta, Inc. (AZTA) on behalf of investors. This follows a significant drop in Azenta's stock price after the company reported disappointing Q2 2026 financial results, including missing EPS and revenue estimates, incurring a goodwill impairment, and reducing its 2026 financial outlook. Shareholders who lost money are encouraged to contact the law firm for potential claims.
FinancialContent - Azenta, Inc. (AZTA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
The Law Offices of Howard G. Smith are investigating Azenta, Inc. (AZTA) on behalf of investors who suffered losses due to possible federal securities laws violations. This follows Azenta's announcement of disappointing Q2 2026 financial results, including missing EPS and revenue consensus, a $149 million goodwill impairment, and a reduced 2026 outlook, which caused its stock price to fall by over 25%. Investors are encouraged to contact the law firm to discuss potential claims.
Azenta, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Azenta, Inc. (AZTA)
Levi & Korsinsky, LLP has initiated an investigation into the officers and directors of Azenta, Inc. (AZTA) following a significant financial loss reported in Q2 FY 2026. The company disclosed a $160.8 million GAAP net loss, primarily due to a $149 million goodwill impairment charge, starkly contrasting with earlier guidance for sustainable, profitable growth. Shareholder losses are being investigated to determine if misleading statements were made regarding Azenta's financial performance.
Azenta, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Azenta, Inc. (AZTA)
Levi & Korsinsky has initiated an investigation into Azenta, Inc. (AZTA) regarding potential misleading statements made by its officers and directors. The investigation follows a sharp drop in Azenta's stock price after the company reported a $160.8 million GAAP net loss in Q2 FY 2026, primarily due to a $149 million goodwill impairment, despite earlier guidance for sustainable growth. Shareholders who incurred losses on their AZTA investment are encouraged to contact Levi & Korsinsky to discuss their legal rights.
AZENTA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is
Bragar Eagel & Squire, P.C. is investigating potential claims against Azenta, Inc. on behalf of its stockholders. This investigation follows Azenta's announcement of disappointing Q2 fiscal 2026 results, revised full-year guidance, and a significant drop in its share price. The law firm is encouraging investors who suffered losses to contact them for a discussion of their legal rights.
Azenta (AZTA) director Quentin Koffey awarded 5,663-share $215K equity grant
Azenta, Inc. director Quentin Koffey received an annual equity grant of 5,663 unrestricted common shares, valued at $215,000, for his Board service under the company's 2020 Equity Incentive Plan. This grant, based on a reference share price of $37.97, brings his direct holdings to 10,698 shares. He also indirectly controls 4,611,752 shares through other entities.
Azenta’s 52% drop validates InvestingPro’s overvalued call By Investing.com
InvestingPro's Fair Value analysis in March 2025 flagged Azenta, Inc. (NASDAQ:AZTA) as significantly overvalued when it traded at $37.15, estimating its worth at $20.08. Since then, the stock has plummeted 51.7% to $17.95, validating the bearish call due to poor fundamentals, missed earnings, and a substantial impairment charge. This case highlights how systematic valuation tools like InvestingPro can help investors identify and avoid overvalued securities.
Number of shareholders of Azenta, Inc. – GETTEX:BA3
This article provides the title "Number of shareholders of Azenta, Inc. – GETTEX:BA3" and indicates that the market is currently closed with no trades. It is supported by TradingView, Inc. and mentions data provision by ICE Data Services and FactSet.
AZENTA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has initiated an investigation into potential securities fraud by Azenta, Inc. (NASDAQ:AZTA) following a significant drop in its stock price. The investigation stems from Azenta's updated full-year outlook, which revealed that its Q2 fiscal 2026 results fell short of expectations due to execution gaps, a cautious demand environment, costs from Automated Stores rework, and a $149 million goodwill impairment charge. The company also reduced its fiscal 2026 revenue and EBITDA margin outlooks, causing its shares to decline by approximately 25%.
Azenta, Inc. 2Q 2026: Revenue $144.8M, Net income ($160.8M), EPS ($3.49) — 10-Q Summary
Azenta, Inc. reported its second-quarter 2026 financial results, showing a slight 1% increase in revenue to $144.8 million compared to the previous year. Despite the revenue growth driven by Sample Management Services and Multiomics, the company posted a significant net loss of ($160.8M) and a diluted loss per share of ($3.49). Azenta is refocusing on its core SMS and Multiomics operations, classifying B Medical Systems as held-for-sale.
AZENTA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP is investigating potential securities fraud claims against Azenta, Inc. (NASDAQ: AZTA) following a significant drop in its stock price. The investigation stems from Azenta's Q2 fiscal 2026 financial results, which fell short of expectations, including a $149 million goodwill impairment charge and reduced full-year outlook. Investors who acquired Azenta securities are encouraged to contact the law firm to learn about their rights.
AZENTA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP is investigating potential securities fraud claims against Azenta, Inc. (NASDAQ: AZTA) following a significant drop in its stock price. This investigation comes after Azenta reported lower-than-expected Q2 2026 financial results, which included an earnings miss, a $149 million goodwill impairment charge, and a reduced full-year revenue outlook. Investors who purchased Azenta securities are encouraged to contact the firm to discuss their rights.
Azenta, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Azenta, Inc. (NASDAQ: AZTA) following the company's Q2 fiscal 2026 financial results which "fell short" of expectations. Azenta reported "execution gaps," a "more cautious demand environment," and a $149 million goodwill impairment charge, leading to a sharp decline in its stock price. The law firm is examining whether Azenta complied with federal securities laws and encourages affected shareholders to join their investigation.
Azenta, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential shareholder claims against Azenta, Inc. (NASDAQ: AZTA) following a sharp decline in stock price. The investigation stems from Azenta's Q2 fiscal 2026 results, which fell short of expectations, included a $149 million goodwill impairment, and led to a reduced full-year outlook. Shareholders who incurred losses are encouraged to contact Johnson Fistel for information on recovering their investments.
Azenta (AZTA) Quarterly Loss Of US$157 Million Reinforces Bearish Margin Narratives
Azenta (AZTA) reported a significant Q2 2026 loss of US$157 million, alongside a basic EPS loss of US$3.41, despite relatively stable revenue. This substantial loss and earnings volatility strengthen the bearish argument regarding the company's margins and execution risks, particularly given ongoing costs for quality remediation and slower-than-market revenue growth. While bullish investors point to a low P/S ratio and analyst forecasts for future profitability, the current financial performance highlights the challenges Azenta faces in achieving stable earnings.
Azenta Down Over 24%, on Pace for Record Percent Decrease -- Data Talk
Azenta Inc. (AZTA) shares fell over 24% and were on pace for a record percentage decrease. The stock had traded down for three consecutive days and its 14-day relative strength index (RSI) indicated it was in oversold territory. The drop was fueled by a disappointing Q2 earnings report and a lowered full-year revenue outlook.
Earnings call transcript: Azenta Inc. misses Q2 2026 estimates, stock drops
Azenta Inc. reported disappointing Q2 2026 results, missing EPS and revenue estimates, which led to a significant stock price drop of 21.22%. The company faced challenges in North America due to a cautious demand environment and recorded substantial goodwill impairment charges. Despite these setbacks and a revised full-year 2026 outlook, Azenta maintains a strong balance sheet and is focusing on strategic transformations and operational efficiencies, particularly in its Multiomics segment.
Azenta, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AZTA)
Azenta, Inc. (AZTA) reported its Q2 2026 earnings, with an EPS of -$0.04, missing estimates by $0.18, and revenue of $144.80M, a 0.96% year-over-year increase, missing estimates by $3.62M. The company published a slide deck in conjunction with its earnings call. This article was prepared by SA Transcripts, which reports on thousands of quarterly earnings calls.
Earnings Flash (AZTA) Azenta, Inc. Posts Q2 Adjusted Loss $0.04 per Share
Azenta, Inc. (AZTA) reported a Q2 adjusted loss of $0.04 per share. This financial update provides key performance indicators for the company's recent quarter.
Earnings Flash (AZTA) Azenta, Inc. Reports Q2 Revenue $145.0M, vs. FactSet Est of $148.5M
Azenta, Inc. (AZTA) reported Q2 revenue of $145.0 million, falling short of the FactSet estimate of $148.5 million. The company is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry, offering services through its Sample Management Solutions and Multiomics segments. Additionally, it operates the B Medical Systems segment focused on temperature-controlled storage solutions.
Azenta (NASDAQ: AZTA) trims 2026 guidance after big Q2 impairment
Azenta, Inc. (NASDAQ: AZTA) reported a significant GAAP net loss of $160.8 million in Q2 fiscal 2026, primarily due to a $149 million non-cash goodwill impairment. Following these results, the company has revised its fiscal 2026 guidance, lowering revenue expectations and anticipating a decline in adjusted EBITDA margin and free cash flow improvement. Additionally, Azenta has extended its long-range plan timeline to 2029 and disclosed delays in the planned $63 million sale of B Medical Systems due to the buyer's financing issues.
Azenta earnings ahead: Can gross margins recover from Q1 pressure?
Azenta Inc. is set to report its fiscal second-quarter earnings, with investors keenly focused on a potential recovery in gross margins after a challenging Q1. Analysts anticipate improved profitability driven by better execution and cost control, despite revenue expectations remaining largely flat. The market is watching for signs that the company's turnaround efforts are gaining traction and if management will reaffirm its full-year guidance.
Azenta (Nasdaq:AZTA) - Stock Analysis
This article provides a detailed stock analysis of Azenta (Nasdaq:AZTA), covering its valuation, future growth prospects, past performance, financial health, management, and ownership. Azenta is currently trading 46.1% below its estimated fair value, with earnings projected to grow by 28.87% annually. Recent analyst commentary and news updates indicate ongoing recalibrations of price targets, reflecting a mix of optimism for long-term growth and caution regarding near-term execution.
How Azenta’s (AZTA) New Multiomics Leadership and RSU Incentives Have Changed Its Investment Story
Azenta has appointed Trey (William E.) Martin III as President of its Multiomics business, granting him 17,790 time-vested RSUs to align his compensation with long-range Multiomics goals. This leadership change and equity incentives are seen as significant for the company's medium-term investment narrative, especially as Azenta prepares to report fiscal Q2 2026 results and reiterate guidance for organic revenue growth. The company's future hinges on its ability to translate modest organic growth from its sample management and Multiomics platforms into improved profitability, despite potential customer budget constraints.
Azenta Q2 2026 Earnings Preview — Street Expects $0.14 EPS
Wall Street analysts anticipate Azenta, Inc. (AZTA) to report Q2 2026 earnings per share of $0.14 on revenue of $148.4 million. This forecast, based on five analysts, shows a 27.3% increase in EPS consensus over the last 30 days, indicating growing optimism despite a longer-term cautious trend. Investors will be focused on whether Azenta can sustain profitability and manage to grow its revenue while operating in the medical instruments and supplies sector.
Conestoga Capital Advisors LLC Sells 151,595 Shares of Azenta, Inc. $AZTA
Conestoga Capital Advisors LLC reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 10.3% in the fourth quarter, selling 151,595 shares but still holding 1,316,401 shares valued at approximately $43.8 million. Other institutional investors like Vanguard and Millennium Management increased their holdings, while Congress Asset Management and MFS opened new significant positions, bringing total institutional ownership to about 99.08%. Azenta reported quarterly EPS of $0.09 and revenue of $148.6 million, with a consensus "Hold" rating and an average price target of $41.33.
Azenta (NASDAQ: AZTA) grants 17,790 RSUs to Multiomics chief
Azenta, Inc. (NASDAQ: AZTA) has granted William E. Martin III, President of Multiomics, 17,790 restricted stock units (RSUs) as compensation under the company's Equity Incentive Plan. These RSUs, valued at $24.24 per share, will vest over three years with installments on April 18, 2027, April 18, 2028, and April 18, 2029. Following this grant, Martin III directly holds 17,790 common shares tied to this award.
Evercore Cuts Azenta (AZTA) Price Target, Keeps Outperform Rating
Evercore ISI has reduced its price target for Azenta (AZTA) from $45 to $35 but maintained an Outperform rating, following a first-quarter preview for the medical technology and life science tools sector. Concurrently, Azenta appointed Trey Martin as President of its Multiomics business to accelerate its long-range plan, focusing on expanding global synthesis capabilities and driving growth. Ginger Zhou will transition out of this role, remaining as an advisor through November 2026.
Evercore Cuts Azenta (AZTA) Price Target, Keeps Outperform Rating
Evercore ISI has reduced its price target for Azenta (AZTA) from $45 to $35 but maintained an Outperform rating following a Q1 preview for the medical technology and life science tools sector. Concurrently, Azenta appointed Trey Martin as President of its Multiomics business, aiming to accelerate the division's long-range plan. Ginger Zhou will transition to an advisory role to ensure a smooth leadership change.
Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) is scheduled to announce its fiscal second quarter 2026 earnings on Wednesday, May 6, 2026, before market open. The company will also host a conference call and live webcast on the same day at 8:30 a.m. Eastern Time to discuss its financial results. Investors and media can access the webcast via Azenta's investor relations website, with a replay available from May 7, 2026.
Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
Azenta Inc. has announced its fiscal 2026 second quarter conference call and webcast. The announcement, delivered via Quantisnow, is related to the company's financial reporting and provides details for investors to access the call. Quantisnow is a platform that provides real-time market data and news to retail investors.
Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
Azenta Inc. has announced its fiscal 2026 second quarter conference call and webcast. The announcement was made via a press release distributed through Quantisnow, a market data and news platform specializing in real-time information for retail investors. The article also provides recent analyst ratings for AZTA.
